Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 4772  
REVIEW ARTICLE
Year : 2021  |  Volume : 20  |  Issue : 4  |  Page : 329-335

Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review


1 Department of Nuclear Medicine and Radiology, Flinders Medical Center, Bedford Park, Australia
2 Centre for Translational Cancer Research, University of South Australia Cancer Research Institute, Adelaide, Australia
3 Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia
4 Department of Nuclear Medicine and Radiology, Flinders Medical Center, Bedford Park; Centre for Translational Cancer Research, University of South Australia Cancer Research Institute, Adelaide; Department of Nuclear Medicine, The Queen Elizabeth Hospital, Woodville, SA, Australia

Correspondence Address:
Dr. Thuan Tzen Koh
Department of Nuclear Medicine and Radiology, Flinders Medical Center, Level 2, Flinders Drive, Bedford Park, SA 5042
Australia
Login to access the Email id


DOI: 10.4103/wjnm.wjnm_160_20

Rights and Permissions

Neuroendocrine neoplasms (NENs) are a very diverse group of tumors with a worldwide rise in incidence. Systemic therapy remains the mainstay treatment for unresectable and/or metastatic NENs. 177Lu-DOTATATE, a radiopharmaceutical which emits beta particles, has emerged as a promising therapy for metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). However, limited treatment options are available particularly after the failure of 177Lu-DOTATATE therapy. This review aims to identify and summarize the available evidence for, and potential adverse events of, targeted alpha-particle therapy (TAT) in the treatment of metastatic NENs, specifically GEP-NENs. The MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases were searched. Two articles which met the inclusion criteria were identified and included in the review. Putative radiopharmaceuticals that can be considered for metastatic NEN treatment include 225Actinium (225Ac)-DOTATATE and 213Bismuth (213Bi)-DOTATOC. There was evidence of partial response using both radiopharmaceutical agents without significant hematological, renal, or hepatotoxicity. Future studies should consider longer term, randomized controlled trials investigating the role of TAT, in particular, 225Ac-DOTATATE, in the treatment of metastatic NENs.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed499    
    Printed24    
    Emailed0    
    PDF Downloaded49    
    Comments [Add]    

Recommend this journal